Brokerages predict that Hill-Rom Holdings Inc (NYSE:HRC) will post sales of $696.40 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Hill-Rom Holdings’ earnings, with the highest sales estimate coming in at $708.90 million and the lowest estimate coming in at $690.10 million. Hill-Rom Holdings reported sales of $655.40 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.3%. The company is expected to issue its next earnings results before the market opens on Friday, July 28th.
On average, analysts expect that Hill-Rom Holdings will report full-year sales of $696.40 million for the current year, with estimates ranging from $2.76 billion to $2.79 billion. For the next financial year, analysts anticipate that the business will report sales of $2.91 billion per share, with estimates ranging from $2.89 billion to $2.93 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Hill-Rom Holdings.
Hill-Rom Holdings (NYSE:HRC) last announced its quarterly earnings results on Friday, April 28th. The medical technology company reported $0.88 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.09. Hill-Rom Holdings had a return on equity of 19.77% and a net margin of 5.80%. The company had revenue of $678.90 million during the quarter, compared to analyst estimates of $654.27 million. During the same quarter in the previous year, the firm posted $0.71 EPS. The firm’s quarterly revenue was up 7.3% on a year-over-year basis.
HRC has been the subject of a number of recent analyst reports. Morgan Stanley raised their price target on Hill-Rom Holdings from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, June 30th. Zacks Investment Research raised Hill-Rom Holdings from a “hold” rating to a “buy” rating and set a $88.00 price target for the company in a report on Monday, June 12th. ValuEngine raised Hill-Rom Holdings from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. Stifel Nicolaus raised their price target on Hill-Rom Holdings from $70.00 to $84.00 and gave the company a “buy” rating in a report on Monday, May 1st. Finally, Barclays PLC lifted their target price on Hill-Rom Holdings from $80.00 to $86.00 and gave the company an “overweight” rating in a research note on Friday, June 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Hill-Rom Holdings presently has a consensus rating of “Buy” and a consensus price target of $88.50.
COPYRIGHT VIOLATION WARNING: “Hill-Rom Holdings Inc (HRC) Expected to Announce Quarterly Sales of $696.40 Million” was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://baseballnewssource.com/markets/hill-rom-holdings-inc-hrc-expected-to-announce-quarterly-sales-of-696-40-million-updated-updated-updated/1197909.html.
Shares of Hill-Rom Holdings (NYSE:HRC) traded up 1.78% on Friday, reaching $84.40. The company’s stock had a trading volume of 220,123 shares. Hill-Rom Holdings has a 52 week low of $49.90 and a 52 week high of $84.40. The stock has a 50-day moving average of $77.56 and a 200 day moving average of $68.18. The stock has a market capitalization of $5.55 billion, a price-to-earnings ratio of 36.46 and a beta of 1.23.
The company also recently announced a quarterly dividend, which was paid on Friday, June 30th. Stockholders of record on Friday, June 16th were paid a $0.18 dividend. The ex-dividend date of this dividend was Wednesday, June 14th. This represents a $0.72 annualized dividend and a dividend yield of 0.87%. Hill-Rom Holdings’s dividend payout ratio (DPR) is currently 31.03%.
In other news, SVP Paul Sherwood Johnson sold 2,078 shares of Hill-Rom Holdings stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $72.30, for a total value of $150,239.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Andreas G. Frank sold 10,660 shares of Hill-Rom Holdings stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $78.62, for a total value of $838,089.20. Following the completion of the sale, the senior vice president now directly owns 28,988 shares of the company’s stock, valued at $2,279,036.56. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the stock. Eqis Capital Management Inc. boosted its stake in Hill-Rom Holdings by 16.0% in the second quarter. Eqis Capital Management Inc. now owns 5,415 shares of the medical technology company’s stock valued at $431,000 after buying an additional 745 shares during the period. James Investment Research Inc. purchased a new stake in Hill-Rom Holdings during the second quarter valued at approximately $1,401,000. Bank of Montreal Can boosted its stake in Hill-Rom Holdings by 2.1% in the second quarter. Bank of Montreal Can now owns 1,007,525 shares of the medical technology company’s stock valued at $80,206,000 after buying an additional 20,495 shares during the period. Atria Investments LLC purchased a new stake in Hill-Rom Holdings during the second quarter valued at approximately $224,000. Finally, Capstone Asset Management Co. boosted its stake in Hill-Rom Holdings by 2.4% in the second quarter. Capstone Asset Management Co. now owns 7,695 shares of the medical technology company’s stock valued at $613,000 after buying an additional 180 shares during the period. 83.86% of the stock is owned by institutional investors.
Hill-Rom Holdings Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with our FREE daily email newsletter.